The FDA placed BPC-157 in Category 2 of the interim 503A bulk-substances list in 2023
Exosome therapy delivers powerful cell messengers to repair tissues, modulate the immune response, and calm overactive pain pathways, providing lasting relief for chronic pain and fibromyalgia
This can reflect either vasogenic or cytotoxic edema, with the latter indicated by a reduction in the ADC (apparent diffusion coefficient)
They are also beneficial for individuals with poor dietary intake of B12 (including vegetarians and vegans), older adults with reduced absorption, patients with digestive conditions like Crohns disease or celiac disease, and those managing conditions like anemia, sciatica, or peripheral neuropathy
B12 also downregulated CSF2 ( P = 0.0071) and CXCL10 ( P = 0.0205) in leukocytes from impaired individuals, although these genes were not differentially regulated when compared to the non-impaired group